Neurol. praxi. 2024;25(6):482-484 | DOI: 10.36290/neu.2024.041

Drug-induced excessive sleepiness

MUDr. Kateřina Seltenreichová, Ph.D.
Centrum pro poruchy spánku, Nemocnice Na Homolce, Praha

Excessive daytime sleepiness (EDS) is a serious issue, with one of the most tragic potential consequences being traffic and other accidents. This review article particularly deals with drug-induced EDS that cannot be explained by negative effects on nocturnal sleep quality and architecture or by inducing nocturnal insomnia and/or the occurrence of parasomnia. It is focused on EDS induced by drugs in themselves; however, the distinction between various pharmacogenetic causes of EDS is not always clear cut. The main emphasis is placed on anti-seizure medications, anxiolytics, antipsychotic drugs, antidepressants, antiparkinsonian drugs, muscle relaxants, antihistamines, opioids, and coanalgesics. The paper also briefly outlines how to manage drug-induced EDS.

Keywords: excessive daytime sleepiness, complete polysomnography, GABA receptors, histamine receptors, depression, schizophrenia.

Received: May 14, 2024; Revised: June 3, 2024; Accepted: June 3, 2024; Prepublished online: June 3, 2024; Published: December 31, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Seltenreichová K. Drug-induced excessive sleepiness. Neurol. praxi. 2024;25(6):482-484. doi: 10.36290/neu.2024.041.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 31.12.2025

    References

    1. Cai K, Nanga RP, Lamprou L, et al. The Impact of Gabapentin Administration on Brain GABA and Glutamate Concentrations: A 7 T 1H­‑MRS Study. Neuropsychopharmacology. 2012;37:2764-2771. Go to original source... Go to PubMed...
    2. Chaneva O. Effects of levetiracetam on sleep architecture and daytime sleepiness. Folia Med Plovdiv. 2021;63(5):631-636. Go to original source... Go to PubMed...
    3. Cooper JA, Tucker VL, Papakostas VI. Resolution of sleepiness and fatigue: A comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. J Psychopharmacol. 2014;28(2):118-24. Go to original source... Go to PubMed...
    4. de Baurepaire R. A Review of the Potential Mechanisms of Action of Baclofen in Alcohol Use Disorder. Front. Psychiatry, 2018. Go to original source... Go to PubMed...
    5. Ferri R, Mogavero MP, Bruni O, et al. Periodic leg movements during sleep associated with antidepressants: A meta­‑analysis. Neurosci Biobehav Rev. 2023;148:105126. Go to original source... Go to PubMed...
    6. Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. Dialogues Clin Neurosci. 2008;10(4):473-481. Go to original source... Go to PubMed...
    7. Freeman D, Taylor KM, Molodynski A, Waite F. Treatable clinical intervention targets for patients with schizophrenia. Schizophr Res. 2019;211:44-50. Go to original source... Go to PubMed...
    8. Heydari M, Isfeedvajani MS. Zolpidem dependence, abuse and withdrawal: A case report. J Res Med Sci. 2013;18(11):1006-1007.
    9. Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ. 2002;324(7352):1483-1487. Go to original source... Go to PubMed...
    10. Kolla BP, Jian­‑Ping He, Kansukhani MP, et al. Excessive Sleepiness and Associated Symptoms in the US adult Population: Prevalence, Correlates and Comorbidity. Sleep Health. 2020;6(1):79-87 (published online 2019). Go to original source... Go to PubMed...
    11. Kraepelin E. Dementia Praecox and Paraphrenia, 1919. In: Textbook of Psychiatry, 8th ed. Barclay, E.S., Translated, Livingston, Edinburgh.
    12. Kuba R. Antiepileptika a jejich klinické použití v epileptologii. Prakt. lékáren. 2010;6(2):62-66.
    13. Kubo N, Shirakawa O, Kuno T, et al. Antimuscarinic effects of antihistamines: Quantitative evaluation by receptor­‑binding assay. Japan J Pharmacol. 1987;43;277-282. Go to original source...
    14. Leurs R. Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti­‑inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32(4):489-98. Go to original source... Go to PubMed...
    15. Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep. 2005;28(1):113-21. Go to original source... Go to PubMed...
    16. Onakpoya IJ, Thomas ET, Lee JJ, et al. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta­‑analysis of randomised clinical trials. BMJ Open. 2019;9(1). Go to original source... Go to PubMed...
    17. Razieh R, Shafiei A, Firouzabadi FD, et al. Evaluation of the efficacy and tolerability of levetiracetam as add­‑on therapy in intractable epilepsy of children. Iran J Child Neurol. 2022;16(2):77-84.
    18. Rosen IM, MD, Aurora RN, MD, Kirsch DB, et al. Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine Position Statement. J Clin Sleep Med. 2019;15(11):1671-1673. Go to original source... Go to PubMed...
    19. Snowman AM, Snyder SH. Cetirizine: Actions on neurotransmitter receptors. J Allergy Clin Imunol. 1990;86:025-8. Go to original source... Go to PubMed...
    20. Tvete IF, Bjørner T, Skomedal T. A 5-year follow­‑up study of users of benzodiazepine: starting with diazepam versus oxazepam. Br J Gen Pract. 2016;66(645):e241-7. Go to original source... Go to PubMed...
    21. Wadzinski J, Franks R, Roane D, et al. Valproate­‑associated hyperammonemic encephalopathy. J Am Board Fam Med. 2007;20(5):499-502. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.